Clinical trials are an important way to improve treatment for people with cancer. While most are continuing during the COVID-19 pandemic, the period of time that clinical trials are available and recruiting may change quickly. If you would like to get involved in a clinical trial, speak to your treatment team or the health service where the clinical trial is being undertaken, to confirm it is open and appropriate for you. For cancer information and support, call Cancer Council's experienced cancer nurses on 13 11 20 Monday to Friday from 9am-5pm.

ASCEND : A Randomised, Double-blinded Phase II Study of Gemcitabine and Nab-Paclitaxel With CEND-1 or Placebo in Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

TwoPhase Two

18+Age Over 18

Pancreas<br/>CancersCancer LocationPancreas
Cancers

Systemic therapy,Treatment | Stomach and upper gastrointestinal tractPancreas

Trial Overview Read MoreRead more

This phase II study is trying to understand the effectiveness of combining a new drug (CEND-1), compared to a placebo, with chemotherapy (gemcitabine and nab-paclitaxel) in people with untreated metastatic pancreatic cancer.
 

This trial is treating patients with pancreatic cancer.

This is a systemic therapy trial.

You may be able to join this trial if:

  • You have been diagnosed with cancer, but have not received any treatment.
  • Your cancer has spread to other parts of the body.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have been diagnosed with a prior or secondary type of cancer.
  • You have had certain treatments, surgical procedures or drugs.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

A Randomised, Double-blinded Phase II Study of Gemcitabine and Nab-Paclitaxel With CEND-1 or Placebo in Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma

Cooperative Group

Australasian Gastro-Intestinal Trials Group (AGITG)

Other Non-Commercial Sponsor

University of Sydney

Summary

This is a double-blind trial and eligible participants will be randomly allocated to either the Experimental Arm or Placebo Comparator Arm. In the Experimental Arm, participants will receive nab-paclitaxel (125mg/m2 intravenously [IV]); CEND-1 (3.2mg/kg IV), and gemcitabine (1000mg/m2) on Day 1, 8 and 15 of each 21-day cycle. In the Placebo Comparator Arm, participants will receive nab-paclitaxel (125mg/m2); placebo (IV); and then Gemcitabine (1000mg/m2) on Day 1, 8 and 15 of each 21-day cycle.

Recruiting Hospitals Read MoreRead more

Border Medical Oncology
Albury
Ms Kate Oates
koates@bordermedonc.com.au
02 6064 1499

Epworth Freemasons, Jreissati Family Pancreatic Centre
East Melbourne
Alishiya Murali
EHJreissatiCentre@epworth.org.au
03 9426 8880

Epworth Richmond, Jreissati Family Pancreatic Centre
Richmond
Alishiya Murali
EHJreissatiCentre@epworth.org.au
03 9426 8880

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next